Back To Search Results

Methotrexate

Editor: Meenal Mittal Updated: 12/11/2024 6:15:17 PM

Indications

Methotrexate is a folic acid antagonist indicated for the treatment of rheumatoid arthritis because of its high potency and efficacy; it can also help treat patients with juvenile idiopathic arthritis.[1] Gubner first suggested methotrexate as a treatment for rheumatoid arthritis after performing a double-blinded, placebo-controlled clinical trial of methotrexate in patients with this condition.[2] 

Aminopterin, the parent compound of methotrexate, was first successfully used to treat childhood leukemia.[3] Today, methotrexate is one of the primary chemotherapeutic choices for various types of cancer. This medication is safe and effective for patients with psoriasis, systemic lupus erythematosus, inflammatory bowel disease, vasculitis, and many other connective tissue diseases.[4] However, the safety and efficacy of methotrexate have not been established in patients with blood dyscrasias, and it is not recommended for pregnant women. 

Methotrexate is also effective for patients who have received a donated organ because of its anti-inflammatory and immunomodulatory activity.[5] Additionally, methotrexate can be combined with anti-TNF agents and is effective for treating patients with ulcerative colitis, carcinoma of the breast, small-cell carcinoma of the lung, epidermal tumors of the head and neck, and carcinoma of the ovary.[6] The medication has the same effects as cyclosporin for patients with graft-versus-host disease. According to the American College of Rheumatology (ACR), methotrexate is strongly preferred over sulfasalazine or hydroxychloroquine as a disease-modifying antirheumatic drug (DMARD) for patients who are DMARD-naïve and present with moderate-to-high disease activity.[7]

FDA-Approved Indications

  • Rheumatoid arthritis
  • Polyarticular juvenile idiopathic arthritis
  • Refractory psoriasis [8] 
  • Acute lymphoblastic leukemia
  • Relapsed or refractory non-Hodgkin lymphoma
  • Breast cancer
  • Head and neck squamous cell carcinoma [9]
  • Meningeal leukemia
  • Osteosarcoma 
  • Cutaneous T-cell lymphoma (mycosis fungoides) [10]
  • Gestational trophoblastic neoplasia [11]

Off-Label Uses

  • Dermatomyositis
  • Pityriasis rubra pilaris
  • Eczema
  • Sarcoidosis
  • ANCA-associated vasculitis

The 2024 guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) recommend that clinicians consider methotrexate or mycophenolate mofetil as alternatives to azathioprine for maintenance therapy in patients who are intolerant to azathioprine for the management of antineutrophil cytoplasmic antibody–associated vasculitis. However, methotrexate should not be used for patients with a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m².[12] The American Academy of Dermatology (AAD) offers a conditional recommendation for the use of methotrexate in adults with moderate-to-severe atopic dermatitis (AD).[13][14]

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Methotrexate has various mechanisms of action, making it an effective treatment for different conditions. When administered as a treatment for cancer, methotrexate acts as an antifolate antimetabolite. The drug is taken up into the cell by human reduced folate carriers (SLC19A1) and forms methotrexate-polyglutamate. The unaltered methotrexate and methotrexate-polyglutamate inhibit the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate into tetrahydrofolate, the active form of folic acid.[15] Tetrahydrofolate is necessary to synthesize the nucleotides of both DNA and RNA. Methotrexate-polyglutamate also inhibits both purine synthase, suppressing the de novo synthesis of purine nucleotides, and thymidylate synthase, thereby preventing DNA synthesis. These separate actions combine to produce a cytotoxic effect, which is the primary reason methotrexate is prescribed as a cancer treatment.[16]

Similarly, methotrexate may be chosen for patients with autoimmune diseases for entirely different mechanisms of action. Methotrexate inhibits the enzyme AICAR transformylase, disrupting the metabolism of adenosine and guanine. This results in adenosine accumulation, which exerts feedback by repressing T-cell activation, downregulating B-cell function, and increasing the sensitivity of activated CD-95 T cells. The combination of these individual processes results in a systemic anti-inflammatory effect. Additionally, methotrexate suppresses methyltransferase activity and inhibits the binding of interleukin-1β to its cell surface receptor.

Pharmacokinetics

Absorption: Methotrexate demonstrates a bioavailability of approximately 60% at doses ≤30 mg/m², reaching peak plasma concentrations between 45 minutes and 6 hours. Taking methotrexate with meals delays absorption, and the drug may undergo enterohepatic recirculation.

Distribution: Methotrexate is 50% protein-bound in serum and competes with reduced folates for active transport across cell membranes. At higher concentrations, passive diffusion becomes a key mechanism for intracellular uptake. After intravenous administration, the initial volume of distribution is 0.18 L/kg, and the steady-state volume ranges from 0.4 L/kg to 0.8 L/kg. Methotrexate is efficiently distributed in the synovial fluid.[17] A patient treated with methotrexate for psoriatic arthritis developed eosinophilic pleural effusions and a hemorrhagic pericardial effusion. Despite discontinuation and corticosteroid treatment, the effusions recurred. Pleural biopsy revealed chronic inflammation with eosinophils, highlighting methotrexate's potential to distribute systemically and cause eosinophilic inflammation in pleural and pericardial space.[18]

Metabolism: Methotrexate is metabolized in the liver and cells to active polyglutamated forms that inhibit dihydrofolate reductase and thymidylate synthetase. These metabolites accumulate in tissues, prolonging the drug's effects. Methotrexate is also converted to 7-hydroxymethotrexate, which has lower solubility than the parent drug.

Elimination: Methotrexate is primarily eliminated via renal excretion. The elimination half-life ranges from 3 to 10 hours at lower doses and 8 to 15 hours following high-dose therapy. Nonlinear elimination may be observed due to renal tubular saturation. Methotrexate may also be minimally excreted in bile (≤10%).

Administration

Available Dosage Forms and Strengths

Methotrexate is administered orally or as an injection (intramuscular, intravenous, intrathecal, or subcutaneous).[19] Methotrexate is available in several formulations, including a 25 mg/mL injectable solution, as well as subcutaneous autoinjectors with the following strengths: 7.5 mg/0.4 mL, 10 mg/0.4 mL, 15 mg/0.4 mL, 17.5 mg/0.4 mL, 20 mg/0.4 mL, 22.5 mg/0.4 mL, and 25 mg/0.4 mL. Methotrexate is also available in prefilled subcutaneous syringes, as 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg tablets, and as a 2 mg/mL oral solution.

Adult Dosage

A thorough patient evaluation is necessary before initiating medical therapy with methotrexate. This evaluation should be supplemented with laboratory testing, which includes a complete blood count with differential, renal function tests (serum creatinine, blood urea nitrogen, and urinalysis), liver function tests (serum bilirubin, AST, ALT, serum albumin), hepatitis serology, and HIV testing.[20] A chest radiograph should also be obtained if appropriate. Specific doses should be calculated based on the indications and renal function.

Oral: This formulation is usually administered weekly as a single dose or divided into doses every 8 hours over a 24-hour period. Folate supplementation (1 mg/d or 5 to 7 mg weekly) should be considered for all patients to prevent bone marrow suppression. In adults, oral absorption is dependent upon the dose taken. Peak serum levels are achievable within 2 hours.

IV: A single-dose autoinjector can deliver various doses, including 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, and 30 mg.[21]

After the initiation of methotrexate therapy, follow-up testing should include cell count (CBC), renal function, and liver function monitoring, which are recommended weekly for 4 weeks and then at least bi-monthly.[22]

Rheumatoid arthritis: The recommended starting dosage is 7.5 mg once weekly, which may be adjusted to achieve an optimal therapeutic response.

Polyarticular juvenile idiopathic arthritis: The recommended starting dosage is 10 mg/m² once weekly, which may be adjusted to achieve an optimal therapeutic response.

Psoriasis: The recommended dosage is between 10 and 25 mg once weekly. Once a satisfactory therapeutic response is achieved, the dose should be reduced to the lowest effective dose.

Neoplastic conditions: Refer to the prescribing information for disease-specific dosing recommendations. High-dose regimens should follow established guidelines, with dose adjustments based on patient response, renal function, and toxicity. Close monitoring is essential to optimize treatment outcomes and minimize adverse effects.

Specific Patient Populations

Hepatic impairment: Patients with a liver condition may be at higher risk for methotrexate-related adverse reactions due to altered elimination. Dose reduction or discontinuation of methotrexate injection should be considered based on the severity of liver dysfunction.

Renal impairment: According to KDIGO guidelines, the dose of methotrexate should be reduced when the patient's glomerular filtration rate (GFR) <60 mL/min/1.73 m². Methotrexate should be avoided for patients with a GFR <15 mL/min/1.73 m². High-dose methotrexate (HDMTX) is commonly used to treat various cancers. While it is generally well-tolerated by most patients, it carries a risk of significant toxicity, particularly acute kidney injury (AKI). This toxicity is primarily due to the crystallization of methotrexate in the renal tubular lumen, which can result in tubular damage. Close monitoring and appropriate preventive measures are essential to minimize the risk of renal complications in patients receiving HDMTX.[23]

Pregnancy considerations: Methotrexate is contraindicated for pregnant women with non-neoplastic diseases due to the risk of embryo-fetal toxicity, including miscarriage, congenital disabilities, and developmental abnormalities. This drug can cause harm when used during pregnancy, especially in the first trimester. For pregnant women with neoplastic diseases, the preservative-free formulation should be used, as benzyl alcohol can cross the placenta. The potential risks to the fetus should be carefully considered.

Breastfeeding considerations: Breastfeeding is generally contraindicated during maternal high-dose methotrexate therapy due to potential risks to the infant. Mothers should be advised to wait at least 1 week after receiving high-dose methotrexate before breastfeeding. To minimize potential exposure, withholding breastfeeding for 24 hours after a low-dose methotrexate administration may reduce the infant's exposure by approximately 40%. If breastfeeding is pursued with long-term low-dose methotrexate, monitoring the complete blood count and liver enzymes is recommended.[24]

Pediatric patients: The safety and efficacy of methotrexate have been established in pediatric patients for polyarticular juvenile idiopathic arthritis, acute lymphoblastic leukemia, meningeal leukemia, non-Hodgkin lymphoma, and osteosarcoma. Methotrexate dosing is typically determined by body surface area and renal function. However, additional research is required to understand better the pharmacokinetics and pharmacodynamics of methotrexate in both pediatric and adult populations.[25]

Older patients: Adjusting the dose according to renal function is necessary to mitigate the risk of toxicity.

Adverse Effects

Even a low dose of methotrexate is not free from adverse effects. The most common adverse effects are gastrointestinal (eg, nausea, vomiting, mucosal ulcers, and loss of appetite). These effects are noted in most patients and are easily managed.[6] The most significant adverse effect of methotrexate is hepatotoxicity. These side effects are similar to folate deficiency and can be prevented by supplementing methotrexate with folic acid.[26] A slightly elevated aminotransferase level is typical, but it is uncommon to have liver steatosis, fibrosis, and cirrhosis when taking a low dose of methotrexate. Over a long duration of treatment, ultrasound scanning and liver biopsy are required to ascertain the liver damage.

Methotrexate is a category X drug and is contraindicated during pregnancy. When prescribing this treatment to any female of reproductive age, the patient must be made aware of its potential for teratogenesis, and double contraception is mandatory. With high-dose methotrexate, patients may also experience mucosal ulceration, which may be a sign of impending methotrexate toxicity. Alopecia, fatigue, fever, increased risk of infection, low white blood cell count, gastrointestinal bleeding, pancreatitis, bone marrow suppression (aplastic anemia), malignancy (lymphoproliferative disorders), infections, and renal failure are other potentially life-threatening side effects.[27][28]

Drug-Drug Interactions

  • Methotrexate is highly plasma protein-bound; any drug displacing it from proteins can increase blood levels. Protein-bound drugs such as oral anticoagulants, phenytoin, salicylates, sulfonamides, sulfonylureas, and tetracyclines may interact with it.
  • Any drug affecting renal clearance may cause an increase in methotrexate levels. Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, TMP, penicillin, warfarin, valproate, proton pump inhibitors, cyclosporin, and cisplatin increase the risk of MTX toxicity in the blood; aminoglycosides, neomycin, probenecid reduces the absorption of MTX.[29][15]
  • The typical interactions are with NSAIDs and PPIs due to the high frequency of concurrent prescriptions.
  • Coadministration of methotrexate with certain medications can alter its plasma concentrations, increasing the risk of severe adverse reactions and potentially reducing the formation of active metabolites, which may decrease its clinical effectiveness. This includes oral antibiotics like neomycin and penicillin, antifolate drugs such as dapsone and pyrimethamine, NSAIDs, and hepatotoxic or nephrotoxic products. Caution is advised when using nitrous oxide in patients receiving methotrexate, as it may exacerbate methotrexate's effects on folate metabolism, increasing the risk of severe adverse reactions. Alternative therapies should be considered.
  • The coadministration of folic acid or its derivatives may reduce methotrexate's effectiveness in treating neoplastic diseases by competing for active transport across cell membranes. Patients should follow their healthcare provider's guidance regarding folic or folinic acid use to ensure optimal treatment outcomes.
  • For patients with immune-mediated inflammatory diseases, methotrexate may adversely affect humoral and cellular immune responses to COVID-19 mRNA vaccines. While specific immunogenicity thresholds correlating with vaccine efficacy remain undefined, these findings suggest that alternative strategies and additional research may be needed.[30]

Contraindications

Methotrexate is contraindicated for patients with hypersensitivity reactions to this medication. Pregnant or breastfeeding patients should avoid using methotrexate due to the elevated risk of teratogenicity and excretion into breast milk. In cases of rheumatoid arthritis or psoriasis, it is contraindicated to use methotrexate in patients with chronic liver disease, cirrhosis, alcoholic hepatitis, or active alcohol use disorder. Methotrexate is not recommended for patients with HIV/AIDS, blood dyscrasias, renal dysfunction, or those undergoing radiotherapy.[28]

Box Warning

  • Embryo-fetal toxicity: Methotrexate is teratogenic and can cause embryo-fetal toxicity, including fetal death. This drug is contraindicated during pregnancy for non-neoplastic diseases. For patients with reproductive potential and neoplastic conditions, counsel regarding the potential risks to the fetus and emphasize the need for effective contraception throughout treatment.

  • Hypersensitivity reactions: Methotrexate is contraindicated in patients with a history of severe hypersensitivity reactions, including anaphylaxis.[31]

  • Severe adverse reactions: Severe adverse reactions, including organ damage and fatalities, have been reported. Vigilant monitoring for toxicities involving the bone marrow, gastrointestinal system, liver, lungs, kidneys, and skin is critical. Based on the clinical severity of adverse events, methotrexate should be withheld or discontinued.

Warnings and Precautions

  • Caution is necessary for using methotrexate for patients who have preexisting blood disorders, such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia.[20]

Monitoring

Patients taking methotrexate should undergo laboratory testing with complete blood count, serum creatinine, and transaminase level monitoring weekly for the first 4 weeks and then at least bimonthly. A complete list of the current medications should be revised to avoid any possible drug interactions before prescribing methotrexate. Liver function tests (serum AST, ALT, and albumin levels) and liver biopsy can also be performed in cases of hepatotoxicity.[20] Creatinine clearance requires monitoring to avoid possible nephrotoxicity; a CrCl of 50 mL/min is necessary before prescribing methotrexate.[28] Monitoring for pulmonary toxicity is also needed as the patients may have a dry cough, fever, or dyspnea. Baseline chest radiographs are recommended to detect interstitial and alveolar infiltrates, hilar adenopathy, pleural effusions, and pulmonary fibrosis.[27] 

Methotrexate may also cause reactivation of tuberculosis, so tests to eliminate the presence of tuberculosis are required. Also, one should monitor for bone marrow toxicity as myelosuppression can occur due to folate deficiency. A sudden dip in blood counts must alert one to that possibility. Key risk factors for methotrexate toxicity include drug interactions and patient-specific factors such as serum albumin and serum calcium. Delayed methotrexate elimination complicates toxicity assessment, making dosing adjustments based on area under the curve (AUC) a more reliable strategy for minimizing adverse effects. These factors underscore the need for personalized approaches, including genetic screening and close monitoring, to optimize methotrexate therapy and reduce the risk of adverse reactions.[32]

Toxicity

Signs and Symptoms of Overdose

High-dose methotrexate (HDMTX) is the term for doses higher than 500 mg/mL. Patients may experience nausea, mucosal ulceration, alopecia, fatigue, fever, increased risk of infection, leukopenia, GI bleeding, pancreatitis, cirrhosis, aplastic anemia, malignancy (lymphoproliferative disorders), infections, interstitial pneumonitis, renal impairment, and teratogenesis.[20]

Management of Overdose

Immediate leucovorin administration is required to manage MTX toxicity. Adequate hydration and urinary alkalinization with sodium bicarbonate are also necessary for patients with acute kidney injury.

The 3 primary treatments for MTX toxicity are leucovorin, thymidine, and glucarpidase.[21] Leucovorin is the reduced active form of folic acid that rescues normal cells from the toxic effects caused by MTX’s inhibition of reduced folates.[33] Leucovorin is particularly effective in preventing myelosuppression, gastrointestinal toxicity, and neurotoxicity during methotrexate treatment. Thymidine rescues cells from the cytotoxic effects of MTX; however, its use is still under investigation and is always given together with the other drugs. Glucarpidase converts methotrexate into the nontoxic metabolites DAMPA and glutamate, thus rapidly removing methotrexate in patients with renal dysfunction. The combination of glucarpidase and leucovorin is a typical therapy for MTX toxicity. A single dose of glucarpidase reduces plasma methotrexate concentrations by 97% or more within 15 minutes. Hydration and urine alkalinization are also continued in patients requiring glucarpidase. Leucovorin therapy should continue for 48 hours after glucarpidase administration.[33]

Hemodialysis and hemoperfusion can also lower MTX levels. Intrathecal overdoses require CSF drainage and exchange, steroids, antidotes, and suspension of the medications that interfere with methotrexate clearance (eg, NSAIDs, salicylates, TMP, penicillin, warfarin, valproate, proton pump inhibitors, cyclosporin, cisplatin). 

According to the Extracorporeal Treatments in Poisoning (EXTRIP) guidelines on methotrexate poisoning, extracorporeal treatments are generally not recommended in patients receiving standard-care folinic acid rescue therapy. However, extracorporeal treatments may be considered in particular circumstances, such as shortly after methotrexate infusion, significant overdose in a patient with kidney failure, pregnancy, or iatrogenic errors like high-dose methotrexate administration to the wrong patient. If extracorporeal treatment is necessary, intermittent high-efficiency hemodialysis is the preferred method.[34]

Enhancing Healthcare Team Outcomes

Measures to improve patient-doctor relationships and sustain treatment continuity should be discussed with the patient before starting treatment with methotrexate to prevent morbidity to a greater extent and increase the life expectancy in cancer patients. The risk of potentially life-threatening side effects, hepatotoxicity, pulmonary toxicity, myelosuppression, and nephrotoxicity should be discussed with the patients.[20][27][28]

  • Advise the patient to call 911 immediately if they develop any signs of infection (immunosuppression), experience coughing, wheezing, or shortness of breath (pulmonary toxicity), or notice unusual bleeding (liver or bone marrow suppression).
  • Inform patients that adverse reactions such as dizziness and fatigue might affect their ability to drive or operate machinery.
  • Inform patients of the risks of adverse effects across multiple organ systems, including gastrointestinal, hematologic, hepatic, infectious, neurologic, pulmonary, renal, and dermatologic.
  • Advise patients for close follow-up.
  • Advise patients to avoid alcohol because of the increased risk of liver disease.
  • Advise patients that methotrexate can cause teratogenicity. Inform both female and male patients of reproductive age that they should practice any 2 forms of birth control, such as abstinence, oral contraceptives, or condom plus foam.
  • Discuss potential drug interactions, particularly salicylates and over-the-counter NSAIDs.
  • Warn patients about the possible development of malignancy, specifically lymphoma.
  • Discuss the importance of proper dosing and administration, that the recommended dose is once weekly, and that improper daily use of the recommended dose has led to fatal toxicity. Make sure that patients fully understand the necessity for close follow-up and monitoring for toxicity.[21]
  • If an accidental overdose occurs, an antidote is available (leucovorin rescue).

Methotrexate can be an effective drug when used appropriately. Still, given its propensity for drug-drug interactions and adverse effects, the collaborative efforts of the entire interprofessional healthcare team are necessary to achieve optimal therapeutic results. This team includes clinicians, specialists, nursing staff, and pharmacists, each providing input based on their discipline to enhance patient benefit while preventing adverse drug outcomes.

References


[1]

Braun J, Rau R. An update on methotrexate. Current opinion in rheumatology. 2009 May:21(3):216-23. doi: 10.1097/BOR.0b013e328329c79d. Epub     [PubMed PMID: 19373092]

Level 3 (low-level) evidence

[2]

Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. The New England journal of medicine. 1985 Mar 28:312(13):818-22     [PubMed PMID: 3883172]

Level 1 (high-level) evidence

[3]

Weinblatt ME. Methotrexate: who would have predicted its importance in rheumatoid arthritis? Arthritis research & therapy. 2018 May 30:20(1):103. doi: 10.1186/s13075-018-1599-7. Epub 2018 May 30     [PubMed PMID: 29848356]


[4]

Bedoui Y, Guillot X, Sélambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, Ralandison S, Gasque P. Methotrexate an Old Drug with New Tricks. International journal of molecular sciences. 2019 Oct 10:20(20):. doi: 10.3390/ijms20205023. Epub 2019 Oct 10     [PubMed PMID: 31658782]


[5]

Chan ES, Cronstein BN. Methotrexate--how does it really work? Nature reviews. Rheumatology. 2010 Mar:6(3):175-8. doi: 10.1038/nrrheum.2010.5. Epub     [PubMed PMID: 20197777]


[6]

Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. The Cochrane database of systematic reviews. 2014 Aug 27:2014(8):CD006618. doi: 10.1002/14651858.CD006618.pub3. Epub 2014 Aug 27     [PubMed PMID: 25162749]

Level 1 (high-level) evidence

[7]

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research. 2021 Jul:73(7):924-939. doi: 10.1002/acr.24596. Epub 2021 Jun 8     [PubMed PMID: 34101387]


[8]

Hsieh TS, Tsai TF. Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. Immunotherapy. 2024 Feb:16(2):115-130. doi: 10.2217/imt-2023-0139. Epub 2023 Dec 19     [PubMed PMID: 38112064]

Level 1 (high-level) evidence

[9]

Ham JC, van Meerten E, Fiets WE, Beerepoot LV, Jeurissen FJF, Slingerland M, Jonker MA, Husson O, van der Graaf WTA, van Herpen CML. Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence. Head & neck. 2020 May:42(5):828-838. doi: 10.1002/hed.26053. Epub 2020 Jan 6     [PubMed PMID: 31903657]

Level 1 (high-level) evidence

[10]

Valipour A, Jäger M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. The Cochrane database of systematic reviews. 2020 Jul 7:7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3. Epub 2020 Jul 7     [PubMed PMID: 32632956]

Level 1 (high-level) evidence

[11]

Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Lurain JR, Massuger L. Diagnosis and management of gestational trophoblastic disease: 2021 update. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2021 Oct:155 Suppl 1(Suppl 1):86-93. doi: 10.1002/ijgo.13877. Epub     [PubMed PMID: 34669197]


[12]

Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney international. 2024 Mar:105(3S):S71-S116. doi: 10.1016/j.kint.2023.10.008. Epub     [PubMed PMID: 38388102]

Level 1 (high-level) evidence

[13]

Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, Eichenfield LF, Frazer-Green L, Paller AS, Schwarzenberger K, Silverberg JI, Singh AM, Wu PA, Sidbury R. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology. 2024 Feb:90(2):e43-e56. doi: 10.1016/j.jaad.2023.08.102. Epub 2023 Nov 7     [PubMed PMID: 37943240]


[14]

Caron AGM, Bloem M, El Khattabi H, de Waal AC, van Huizen AM, Denswil NP, Gerbens LAA, Spuls PI. The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review. The Journal of dermatological treatment. 2024 Dec:35(1):2292962. doi: 10.1080/09546634.2023.2292962. Epub 2023 Dec 20     [PubMed PMID: 38124505]

Level 1 (high-level) evidence

[15]

Mikhaylov D, Hashim PW, Nektalova T, Goldenberg G. Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits. The Journal of clinical and aesthetic dermatology. 2019 Jun:12(6):46-54     [PubMed PMID: 31360288]


[16]

Singh RK, van Haandel L, Kiptoo P, Becker ML, Siahaan TJ, Funk RS. Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model. European journal of pharmacology. 2019 Jun 15:853():264-274. doi: 10.1016/j.ejphar.2019.03.052. Epub 2019 Apr 2     [PubMed PMID: 30951714]


[17]

Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, Erre GL, Tommasi S. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Therapeutic advances in cardiovascular disease. 2023 Jan-Dec:17():17539447231215213. doi: 10.1177/17539447231215213. Epub     [PubMed PMID: 38115784]

Level 3 (low-level) evidence

[18]

Cudzilo C, Aragaki A, Guitron J, Benzaquen S. Methotrexate-induced pleuropericarditis and eosinophilic pleural effusion. Journal of bronchology & interventional pulmonology. 2014 Jan:21(1):90-2. doi: 10.1097/LBR.0000000000000031. Epub     [PubMed PMID: 24419196]


[19]

Cheng L. Precision dosage of methotrexate in psoriasis. The British journal of dermatology. 2019 Oct:181(4):660-661. doi: 10.1111/bjd.18273. Epub 2019 Jul 28     [PubMed PMID: 31353452]


[20]

Shetty A, Cho W, Alazawi W, Syn WK. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease. The American journal of the medical sciences. 2017 Aug:354(2):172-181. doi: 10.1016/j.amjms.2017.03.014. Epub 2017 Mar 14     [PubMed PMID: 28864376]


[21]

Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis-A review. British journal of clinical pharmacology. 2019 Oct:85(10):2228-2234. doi: 10.1111/bcp.14057. Epub 2019 Aug 9     [PubMed PMID: 31276602]


[22]

Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. The Cochrane database of systematic reviews. 2014 Aug 26:2014(8):CD006884. doi: 10.1002/14651858.CD006884.pub3. Epub 2014 Aug 26     [PubMed PMID: 25157445]

Level 1 (high-level) evidence

[23]

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. The oncologist. 2016 Dec:21(12):1471-1482     [PubMed PMID: 27496039]


[24]

. Methotrexate. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000400]


[25]

Yang Y, Liu Z, Chen J, Wang X, Jiao Z, Wang Z. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review. European journal of clinical pharmacology. 2024 Jan:80(1):11-37. doi: 10.1007/s00228-023-03579-0. Epub 2023 Nov 7     [PubMed PMID: 37934204]

Level 1 (high-level) evidence

[26]

Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumatoid arthritis. An update. Drugs. 1994 Jan:47(1):25-50     [PubMed PMID: 7510620]

Level 3 (low-level) evidence

[27]

Gohar A. Response to 'Reply to Gohar on "Lungs, methotrexate and psoriasis", a comment on "Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis"'. Clinical and experimental dermatology. 2019 Dec:44(8):948. doi: 10.1111/ced.14002. Epub 2019 May 6     [PubMed PMID: 31058367]


[28]

Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. The Journal of rheumatology. 1995 Jan:22(1):38-40     [PubMed PMID: 7699678]

Level 2 (mid-level) evidence

[29]

Tukukino C, Wallerstedt SM. Drug information centre queries and responses about drug interactions over 10 years-A descriptive analysis. Basic & clinical pharmacology & toxicology. 2020 Jan:126(1):65-74. doi: 10.1111/bcpt.13294. Epub 2019 Aug 12     [PubMed PMID: 31310705]


[30]

Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, Koralov SB, Atreya R, Tascilar K, Allen JR, Castillo R, Cornelius AR, Rackoff P, Solomon G, Adhikari S, Azar N, Rosenthal P, Izmirly P, Samuels J, Golden B, Reddy SM, Neurath MF, Abramson SB, Schett G, Mulligan MJ, Scher JU. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Annals of the rheumatic diseases. 2021 Oct:80(10):1339-1344. doi: 10.1136/annrheumdis-2021-220597. Epub 2021 May 25     [PubMed PMID: 34035003]


[31]

Kar A, Mills KA. Severe methotrexate hypersensitivity during treatment for Gestational trophoblastic Neoplasia: Case Report and considerations for management. Gynecologic oncology reports. 2024 Apr:52():101364. doi: 10.1016/j.gore.2024.101364. Epub 2024 Mar 9     [PubMed PMID: 38495802]

Level 3 (low-level) evidence

[32]

Li W, Mo J, Yang Z, Zhao Z, Mei S. Risk factors associated with high-dose methotrexate induced toxicities. Expert opinion on drug metabolism & toxicology. 2024 Apr:20(4):263-274. doi: 10.1080/17425255.2024.2332366. Epub 2024 Mar 19     [PubMed PMID: 38501267]

Level 3 (low-level) evidence

[33]

Van der Beek JN, Oosterom N, Pieters R, de Jonge R, van den Heuvel-Eibrink MM, Heil SG. The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review. Critical reviews in oncology/hematology. 2019 Oct:142():1-8. doi: 10.1016/j.critrevonc.2019.07.003. Epub 2019 Jul 9     [PubMed PMID: 31323533]

Level 1 (high-level) evidence

[34]

Ghannoum M, Roberts DM, Goldfarb DS, Heldrup J, Anseeuw K, Galvao TF, Nolin TD, Hoffman RS, Lavergne V, Meyers P, Gosselin S, Botnaru T, Mardini K, Wood DM, EXTRIP workgroup. Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clinical journal of the American Society of Nephrology : CJASN. 2022 Apr:17(4):602-622. doi: 10.2215/CJN.08030621. Epub 2022 Mar 2     [PubMed PMID: 35236714]

Level 1 (high-level) evidence